title: Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes.
abstract: Here, we report a cationic nanolipoplex as a pulmonary cellular delivery system for small-interfering RNA (siRNA). Six nanoliposomes differing in cationic lipids were formulated and screened in vitro and in vivo for cellular delivery functions in lung cells/tissues. Although the six nanoliposomes showed similar siRNA delivery efficiency in vitro, they exhibited significant differences in pulmonary cellular delivery functions in vivo. Among the various nanoliposomes, cationic dioleoyl-sn-glycero-3-ethylphosphocholine and cholesterol (ECL)-based nanoliposomes showed the highest pulmonary cellular delivery in vivo and the lowest cytotoxicity in vitro. The delivery efficiency of fluorescent siRNA in ECL nanoliposomes was 26.2-fold higher than that of naked siRNA in vivo. Treatment with Mcl1 (myeloid cell leukemia sequence 1)-specific siRNA (siMcl1) using ECL nanolipoplexes reduced target expression in B16F10 cell lines, whereas control, luciferase-specific siGL2 in ECL nanolipoplexes did not. In metastatic lung cancer mouse models induced by B16F10 or Lewis lung carcinoma (LLC) cells, intratracheal administration of siMcl1 in ECL nanolipoplexes significantly silenced Mcl1 mRNA and protein levels in lung tissue. Reduced formation of melanoma tumor nodules was observed in the lung. These results demonstrate the utility of ECL nanoliposomes for pulmonary delivery of therapeutic siRNA for the treatment of lung cancers and potentially for other respiratory diseases.
authors: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
authors: Gayong
authors: G
authors: Shim
authors: Hyun-Woo
authors: HW
authors: Choi
authors: Sangbin
authors: S
authors: Lee
authors: Junhyeok
authors: J
authors: Choi
authors: Yong Hee
authors: YH
authors: Yu
authors: Da-Eui
authors: DE
authors: Park
authors: Yongseok
authors: Y
authors: Choi
authors: Chan-Wha
authors: CW
authors: Kim
authors: Yu-Kyoung
authors: YK
authors: Oh
mesh_terms: D000818:Animals; D015153:Blotting, Western; D045744:Cell Line, Tumor; D005260:Female; D005434:Flow Cytometry; D008081:Liposomes / Q000737:chemistry*; D008168:Lung / Q000378:metabolism* / Q000473:pathology*; D008175:Lung Neoplasms / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D034741:RNA, Small Interfering / Q000235:genetics* / Q000627:therapeutic use; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D008081:Liposomes; D034741:RNA, Small Interfering
references: J Surg Res. 1999 Aug;85(2):339-45
references: 10423338
references: J Pharm Sci. 1999 Sep;88(9):896-904
references: 10479351
references: Bioconjug Chem. 2007 Jul-Aug;18(4):1131-9
references: 17488066
references: Mycoses. 2009 May;52(3):239-45
references: 19383006
references: Biomaterials. 2011 Dec;32(36):9785-95
references: 21937102
references: AAPS J. 2010 Dec;12(4):492-503
references: 20544328
references: Nat Biotechnol. 2010 Feb;28(2):172-6
references: 20081866
references: J Control Release. 2011 Sep 25;154(3):275-84
references: 21699935
references: Biomaterials. 2011 Jan;32(3):849-57
references: 20926129
references: J Liposome Res. 2006;16(4):373-89
references: 17162579
references: J Control Release. 2011 Oct 10;155(1):60-6
references: 20971142
references: J Control Release. 2011 Apr 10;151(1):51-6
references: 21223987
references: Int J Pharm. 2010 May 10;390(2):198-207
references: 20116418
references: Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):1203-9
references: 20381448
references: Mol Ther. 2005 Jun;11(6):990-5
references: 15922971
references: BMC Cancer. 2011 Nov 14;11:485
references: 22078414
references: J Liposome Res. 2011 Dec;21(4):306-14
references: 21457078
references: Mol Ther. 2012 Jan;20(1):91-100
references: 21988874
references: Acc Chem Res. 2012 Jul 17;45(7):961-70
references: 21905687
references: Adv Drug Deliv Rev. 2012 Jan;64(1):1-15
references: 21356260
references: PLoS One. 2011;6(6):e21106
references: 21698156
references: Mol Ther. 2011 Dec;19(12):2163-8
references: 21971426
references: Biotechnol J. 2011 Sep;6(9):1130-46
references: 21744502
references: Mol Ther. 2005 May;11(5):801-10
references: 15851018
references: Mol Pharm. 2007 Jul-Aug;4(4):615-23
references: 17408283
references: Am J Respir Crit Care Med. 2008 Jul 1;178(1):60-73
references: 18310482
references: J Control Release. 2012 Jan 10;157(1):141-8
references: 21864597
references: Biomaterials. 2011 Sep;32(26):6302-15
references: 21624650
references: Nat Biotechnol. 2008 May;26(5):561-9
references: 18438401
references: FEBS J. 2010 Dec;277(23):4814-27
references: 21078116
references: Biochim Biophys Acta. 2013 Feb;1828(2):412-8
references: 23092705
references: Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8
references: 21862980
references: Hum Gene Ther. 1998 Sep 20;9(14):2083-99
references: 9759935
references: J Control Release. 2012 Jun 10;160(2):177-81
references: 22019557
references: Oligonucleotides. 2009 Jun;19(2):103-16
references: 19374532
references: Biophys J. 1999 Nov;77(5):2612-29
references: 10545361
references: Eur J Clin Invest. 2011 Feb;41(2):221-32
references: 20964680
references: Cancer Biol Ther. 2005 Mar;4(3):267-76
references: 15753661
references: Mol Pharm. 2008 Jul-Aug;5(4):559-66
references: 18491918
references: Nat Med. 2005 Sep;11(9):944-51
references: 16116432
references: Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62
references: 19422869
references: J Control Release. 2005 Oct 3;107(2):276-87
references: 16054724
references: Mol Cancer Ther. 2009 Nov;8(11):3162-70
references: 19887550
references: Biomaterials. 2012 Sep;33(25):5924-34
references: 22652024
references: Med Oncol. 2012 Sep;29(3):1681-6
references: 21993632